Incyte Corporation

INCYintermediary

Incyte is a specialty biopharmaceutical company focused on oncology and inflammation, anchored by the blockbuster JAK inhibitor Jakafi and expanding into dermatology with Opzelura.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($3.9B)

Data statis (memuat keuangan langsung…)

Jakafi (55%)

Opzelura (18%)

Other Products (12%)

Royalties & Milestones (15%)

Komposisi segmen dan pelanggan utama

Detail produk

Jakafi (ruxolitinib)55%

First-in-class JAK1/JAK2 inhibitor for myelofibrosis and GVHD

Opzelura (ruxolitinib cream)18%

Topical JAK inhibitor for atopic dermatitis and vitiligo

Monjuvi (tafasitamab)8%

Anti-CD19 antibody for diffuse large B-cell lymphoma

Royalties & Pipeline19%

Royalties from Pemazyre, Zynyz, and pipeline collaboration payments

Hubungan Rantai Pasok

Pesaing

Eli Lilly and Company

JAK inhibitor market (Olumiant)

Dampak: Medium — competing JAK inhibitors

AbbVie Inc.

JAK inhibitor market (Rinvoq)

Dampak: High — Rinvoq is major JAK competitor

Pelanggan Utama

Walgreens Boots Alliance

Specialty pharmacy distribution

Dampak: Medium — pharmacy channel

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Incyte Corporation.

Info Perusahaan

Kantor Pusat

Wilmington, Delaware, USA

Didirikan

1991

Karyawan

2,300+

Situs Web

incyte.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor